China Jo-Jo Drugstores, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CJJD research report →
Price Chart
About the company
China Jo-Jo Drugstores, Inc. , along with its subsidiary entities, functions as a prominent retailer and distributor of a wide array of pharmaceutical and healthcare products across the People's Republic of China. Its operations are structured into four distinct segments: retail pharmacies, an online drugstore, wholesale drug distribution, and the cultivation of medicinal herbs.
- CEO
- Lei Liu
- IPO
- 2009
- Employees
- 939
- HQ
- Hangzhou, CN
Get TickerSpark's AI analysis on CJJD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.95M
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.01
- P/B
- 0.02
- EV/EBITDA
- 10.57
- Div Yield
- 0.00%
- Gross Margin
- 3.60%
- Op Margin
- -1.30%
- Net Margin
- -0.95%
- ROE
- -3.54%
- ROIC
- -3.87%
Latest fiscal year · YoY change
- Revenue
- $154.54M+3.8%
- Gross Profit
- $31.11M-9.3%
- Op Income
- $-3,534,563
- Net Income
- $-4,234,228+80.0%
- EPS
- $-2.93+92.9%
- OCF Growth
- +3.9%
- FCF Growth
- -13.5%
- 52W High
- $4.50
- 52W Low
- $0.85
- 50D MA
- $1.59
- 200D MA
- $1.94
- Beta
- -0.15
- RSI (14)
- 45
- Avg Volume
- 418.36K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
China Jo-Jo posted sharply lower revenue in fiscal Q2, but gross margin improved on better wholesale profitability and online pharmacy sales grew strongly.· November 15, 2013
- Revenue fell 36.8% year over year to $16.9 million, mainly because wholesale sales declined.
- Gross profit was $2.9 million and gross margin improved to 17.8% from 12.5%, helped by higher wholesale profit margin.
- Online pharmacy sales increased 85.6% to $1.6 million as the company expanded cooperation with B2C vendors like Taobao.
- Sales and marketing expenses rose 41.5% due to the 10-year anniversary campaign, but management expects them to decline in Q3.
- Management said it is prioritizing profitability over volume in wholesale, focusing more on hospitals and higher-margin customers.
For fiscal 2014 second quarter, revenue decreased 36.8% year over year to $16.9 million from $26.7 million. Gross profit decreased 13.8% to $2.9 million, while gross margin improved to 17.8% from 12.5%. Operating loss was $0.5 million versus operating income of $9,000 a year ago, and net loss was $1.0 million; the company also reported a separate net loss of $0.5 million in Dr. Liu’s remarks, before taking into account $1.3 million of marketing practice related to the 10-year anniversary. Online pharmacy sales rose 85.6% to $1.6 million. For guidance, management said sales and marketing expenses are expected to be lower in the third quarter of fiscal 2014, and it expects to continue opening clinics next to drugstores, reducing G&A and financing expenses, and focusing on more profitable wholesale customers.
Dr. Liu’s message was that the business is shifting toward higher-quality growth rather than chasing sales volume. He highlighted store closures as a reason for slightly lower drugstore sales, but said same-store sales grew and the company is adding clinics and doctors to improve customer service and drive traffic. He also framed China’s healthcare reform and the industry outlook as positive and said he believes market conditions will improve later in the year and that the company can grow faster over the next three years.
Frank Zhao said the quarter’s revenue decline was driven primarily by lower wholesale sales, while gross margin improved because wholesale profit margin increased. He noted retail gross margin averaged 23.0% and wholesale gross margin averaged 10.6%, and said online pharmacy sales increased to $1.6 million from $0.9 million. He also pointed to higher sales and marketing expense from the anniversary campaign, a $0.8 million reduction in G&A largely tied to a lower allowance for advances to suppliers, and ended the quarter with $6.3 million of cash, $46.8 million in current assets, and $32.3 million in current liabilities.
There were no analyst questions on the call. Management did, however, address investor concerns preemptively by explaining that the company is intentionally reducing low-margin wholesale volume in favor of profitability, even if that affects first-tier distributor status. They also said the 10-year anniversary marketing spend was temporary and expected sales and marketing expenses to come down in the third quarter.
The positive case from this call is that China Jo-Jo is showing margin improvement even as it retools the business. Online pharmacy growth was strong, same-store sales were said to be up, and management believes adding clinics, hiring more doctors, and focusing on higher-margin wholesale customers can improve future performance. The company also sounded confident about China’s healthcare reform and the industry outlook.
The main risks are that revenue fell sharply, wholesale sales are under pressure, and the company is willingly giving up volume to pursue profitability. Gross margin improved, but net results were still negative and sales and marketing expenses spiked because of the anniversary campaign. Management’s strategy could also limit distributor status and may take time to translate into stronger top-line growth.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 59.7%
- Shares Outstanding
- 6.54M
- Float Shares
- 3.91M
of shares held by institutions
1 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Hillhouse Investment Management, Ltd. | 4.84M | 0 |
| Ladenburg Thalmann Financial Services Inc. | 180 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 28, 18 | Liu Lei | other | 225,000 |
| Mar 30, 18 | Liu Lei | other | 900,000 |
| Mar 30, 18 | Zhao Ming | other | 30,000 |
| Jan 19, 17 | Hillhouse Capital Management, Ltd. | other | 0 |
| Oct 11, 16 | Liu Lei | other | 949,000 |
| Nov 27, 15 | Zhao Ming | other | 10,000 |
| Nov 27, 15 | Qi Li | other | 160,000 |
| Nov 27, 15 | LEI LI | other | 210,000 |
| Nov 27, 15 | Gu Genghua | other | 10,000 |
| Nov 18, 14 | Gu Genhua | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CJJD coverage
Recent articles, reports, and earnings notes.
No research on CJJD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CJJD report →China Jo-Jo Drugstores Announces Strategic Business Restructuring to Strengthen Wholesale Business for Greater Profitability and Growth
prnewswire.com · Feb 3
China Jo-Jo Drugstores Reports Fiscal Year 2024 Financial Results
prnewswire.com · Jul 30
China Jo-Jo Drugstores Announces $3.37 Million Registered Direct Offering
prnewswire.com · Jun 11
China Jo-Jo Drugstores Announces Changes to Board of Directors
prnewswire.com · May 31
China Jo-Jo Drugstores Announces $2.74 Million Registered Direct Offering
prnewswire.com · May 10
China Jo-Jo Drugstores Announces $1.53 Million Registered Direct Offering
prnewswire.com · Apr 29
China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price Requirement
prnewswire.com · Mar 19
China Jo-Jo Drugstores, Inc. Announces 1-for-20 Reverse Stock Split
prnewswire.com · Feb 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.